CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 250 enrolled
Drug / intervention
nirmatrelvir, ritonavirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06016556
NCT06016556N/ACompleted
CompareCT.gov

A Retrospective Observational Non-Interventional Study (NIS) to Assess Patient Characteristics and Healthcare Resource Use (HCRU) Among COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir (PAXLOVID TM) in the Kingdom of Saudi Arabia (KSA).

Pfizer·observational·Posted Aug 29, 2023·Updated Jun 5, 2025

In Brief

An observational study evaluating nirmatrelvir, ritonavir for Covid-19. Completed, enrolled 250 participants across 3 sites.

Detailed Summary

The aim of this study is to describe the baseline demographic, clinical characteristics, and Healthcare Resource Use (HCRU) of adult (≥18 years) COVID-19 patients who have been prescribed nirmatrelvir, ritonavir treatment.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCovid-19
CountriesSaudi Arabia
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedAug 29, 2023
Enrollment StartOct 17, 2023
Primary CompletionApr 9, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.8 years ago

Interventions

nirmatrelvir, ritonavirdrug

single cohort